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Abstract: The majority of genes contributing to the heritable component of blood pressure remain 
unidentified, but there is substantial evidence to suggest that common polymorphisms at loci 
involved in the biosynthesis of the corticosteroids aldosterone and cortisol are important. This view 
is supported by data from genome-wide association studies that consistently link the CYP17A1 locus 
to blood pressure. In this review article, we describe common polymorphisms at three steroidogenic 
loci (CYP11B2, CYP11B1 and CYP17A1) that alter gene transcription efficiency and levels of key 
steroids, including aldosterone. However, the mechanism by which this occurs remains unclear. 
While the renin angiotensin system is rightly regarded as the major driver of aldosterone secretion, 
there is increasing evidence that the contribution of corticotropin (ACTH) is also significant. In light 
of this, we propose that the differential response of variant CYP11B2, CYP11B1 and CYP17A1 genes 
to ACTH is an important determinant of blood pressure, tending to predispose individuals with an 
unfavourable genotype to hypertension. 
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1. Introduction 
The importance of hypertension as a risk factor for cardiovascular and cerebrovascular disease 
is well established. In addition to the environmental and lifestyle factors known to influence an 
individual’s blood pressure, there is also a substantial heritable component, estimated to account for 
~40% of the phenotype [1]. Over the last few decades, several large-scale studies have been mounted 
to identify the locations of the genetic polymorphisms underlying this effect but, so far, only 50 or so 
loci have been significantly associated with blood pressure, accounting for <5% of the heritable 
component. A recent study found that most of the heritability influencing systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) is attributable to common genetic polymorphisms, defined 
as those with a minor allele frequency (MAF) greater than 0.1, located in non-coding regions that are 
probably cis-regulatory [2]. Identification of these unknown polymorphisms is highly desirable, as it 
will lead to greater understanding of the mechanisms underlying blood pressure homeostasis, 
thereby improving the treatment and differential diagnosis of hypertension. Investigators have 
employed contrasting strategies in this search, some favouring the hypothesis-free approach of the 
genome-wide association study (GWAS) on the basis that this may identify genes previously 
unsuspected genes of being significant mediators of blood pressure homeostasis. Others, ourselves 
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included, have favoured a candidate gene approach, reasoning that many of the responsible loci are 
likely to be found among those participating in the blood pressure regulatory pathways. One such 
pathway is the biosynthesis of aldosterone, primarily under the regulation of the renin–angiotensin 
system. 
Aldosterone is formed through sequential modifications to cholesterol catalysed by a series of 
steroidogenic enzymes present in the adrenocortical zona glomerulosa; the adjacent zona fasciculata, 
owing to a slightly different combination of enzymes, synthesises the major glucocorticoid cortisol 
[3]. There are several reasons to believe that the genes encoding these steroidogenic enzymes 
contribute to blood pressure variability. Firstly, aldosterone is a key regulator of blood pressure, and 
the secretion rates and plasma levels of aldosterone are heritable traits [4,5]. Secondly, severe 
disruption of this pathway by rare monogenic disorders affecting steroidogenic enzyme function and 
therefore steroid phenotype can dramatically affect blood pressure [6]. Given that these rare 
mutations have such severe outcomes, much of our work has been based on the hypothesis that more 
common but mild functional polymorphisms also exist at these steroidogenic loci. Such 
polymorphisms, influencing the expression or function of the steroidogenic enzymes, would have 
more subtle effects on steroid phenotype than their rarer, more severe counterparts but would 
nonetheless result in small but clinically significant increases in average blood pressure, ultimately 
predisposing carriers in combination with other heritable and environmental factors to hypertension. 
In this article, we summarise our research into common functional polymorphisms, at three 
steroidogenic loci that we believe contribute to the heritable component of blood pressure: CYP11B2, 
CYP11B1 and CYP17A1. We then discuss the importance of corticotropin (ACTH) to the regulation 
of all three genes, present evidence to suggest that this is an underappreciated factor in the long-term 
regulation of aldosterone secretion, and propose that the differential response of these polymorphic 
loci to ACTH may predispose their carriers to raised blood pressure and, ultimately, hypertension. 
2. CYP11B2 
Given its functional role, the CYP11B2 gene is an obvious blood pressure locus candidate. It 
encodes aldosterone synthase (responsible for the three final stages of aldosterone biosynthesis, from 
11-deoxycorticosterone onward), which is the only adrenocortical steroidogenic enzyme unique to 
the production of aldosterone. The renin-angiotensin system (RAS) and raised extracellular 
potassium concentration are the principal stimulators of CYP11B2 expression; ACTH is generally 
regarded as having only a short-lived effect, of far less physiological significance than the other 
factors [3]. The potential for modified CYP11B2 gene expression to cause significant blood pressure 
effects is most starkly illustrated by the rare monogenic condition, glucocorticoid-remediable 
aldosteronism (GRA), where unequal crossing-over of this locus with that of the CYP11B1 gene (see 
below), leads to vastly increased expression of aldosterone synthase, elevating levels of aldosterone 
and resulting in severe hypertension [6]. Clearly, any CYP11B2 polymorphism with a role in 
population blood pressure variation should be much more common than GRA-causing mutations, 
and less pronounced in its effect. In order to support the hypothesis that CYP11B2 is an important 
blood pressure locus, it was therefore necessary to demonstrate firstly that such common 
polymorphisms exist at the CYP11B2 locus and secondly that they have a functional effect on steroid 
phenotype. In the 30 years since its sequence was first published [7], numerous common CYP11B2 
polymorphisms have indeed been identified, the most studied of which is the rs1799998 C/T single-
nucleotide polymorphism (SNP), also referred to as “-344” given its base position relative to the gene 
transcription start site. It is extremely common—its minor allele frequency (MAF) is ~0.43 in Western 
European populations [8] and studies have shown that its T allele associates with higher excretion 
rate of the major urinary aldosterone metabolite, tetrahydroaldosterone (THaldo) [9]. However, no 
clear consensus has emerged on whether this polymorphism associates with changes in blood 
pressure [10–13]. Meta-analysis of 42 individual studies did show an association of rs1799998 with 
essential hypertension, but not with systolic or diastolic blood pressure [10]. According to in vitro 
studies, the effect of this SNP on CYP11B2 gene transcription is significant only following stimulation 
with angiotensin II; even then, the effect is small [14]. We believe this lack of clarity regarding 
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rs1799998 effect may be due to its having no functional impact itself, and from it being in tight but 
not complete linkage disequilibrium (LD) with a functional polymorphism lying nearby. One such 
polymorphism, which we have studied extensively, is rs13268025. 
The rs13268025 polymorphism is a C/T SNP positioned 1651 bases upstream of the CYP11B2 
transcription start site; its alleles are of almost equal frequency in our West of Scotland study 
population (MAF = 0.47) and it displays a high degree of LD with rs1799998 (D’ > 0.95). Our study of 
60 normotensive subjects showed that those homozygous for the C allele excreted significantly higher 
quantities of THaldo in a 24 h period than the T homozygotes [15]. Reporter gene assays compared 
the transcriptional activity of the CYP11B2 promoter in its alternative rs13268025 forms and were 
consistent with our in vitro studies: this SNP at the 1651 position significantly affected gene activity, 
with the C form being more transcriptionally active under basal conditions. This difference in activity 
between the alternative alleles became even more pronounced following angiotensin II stimulation. 
We have linked this change in activity to the disruption of a binding site for the transcriptional 
repressor molecule apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1) at the 1651 position. 
APEX1 has lower affinity for the C form of rs13268025, reducing its inhibitory effect on CYP11B2 
transcription [15]. (Interestingly, although knockout of APEX1 is lethal in mice, heterozygous null 
mice are viable and have markedly elevated blood pressure [16].) 
So, in rs13268025 we have a common polymorphism, carried by approximately half of our study 
population in either homozygotic or heterozygotic form, which alters transcriptional activity of the 
aldosterone synthase gene and associates with a corresponding change in steroid phenotype, while 
also being physically linked to a well-researched polymorphism at the same locus (rs1799998), which 
has itself been significantly associated with functional effects. This identifies CYP11B2 as a locus 
harbouring at least one common polymorphism of functional effect that could influence blood 
pressure and predispose carriers of the “derepressed” C allele to hypertension.  
Surprisingly, the strongest association of CYP11B2 genotype with steroid phenotype to emerge 
from these studies was not with aldosterone but with 11-deoxysteroids, which one would expect to 
be primarily influenced by CYP11B1, the gene encoding the 11β-hydroxylase enzyme, rather than 
CYP11B2 [17]. This relationship between CYP11B2 polymorphisms and indices of CYP11B1 function 
is not as unlikely as it might first appear; the two genes lie side by side on human chromosome 8, 
approximately 40 kilobases apart, and our studies show that their physical linkage could underlie 
this observation. 
3. CYP11B1 
CYP11B1 encodes 11β-hydroxylase responsible for the final catalytic conversion in the 
biosynthesis of cortisol. The gene is expressed within the adrenocortical zona fasciculata, and to a 
lesser extent the zona reticularis, predominantly under the regulation of ACTH, acting through cyclic 
AMP (cAMP) as a second messenger. The strict zonal distribution of expression within the normal 
adrenal gland dictates that CYP11B1 is not coexpressed with CYP11B2, expression of which is 
confined to the zona glomerulosa [6]. Nevertheless, strong association of the CYP11B2 polymorphism 
rs1799998 with indices of 11β-hydroxylase activity, such as levels of urinary 11-deoxycortisol 
metabolites, have been observed in several studies [17–19]. This is the result of LD extending across 
the entire digenic locus, causing certain CYP11B2 polymorphisms to associate with functional 
CYP11B1 SNPs and, therefore, 11β-hydroxylation of steroids. 
One such functional SNP at CYP11B1 is the G/T SNP rs142570922, located 1889 bases upstream 
of the transcription start site. Analysis of 408 hypertensive subjects show that, in comparison to 
carriers of the major G allele (where MAF = 0.49), those with the minor T allele are predisposed to a 
higher ratio of tetrahydrodeoxycortisol (THS) to cortisol metabolites in their urine, reflecting lower 
11β-hydroxylation efficiency [20]. Subsequent analysis of adrenal tissue from individuals 
heterozygous for rs142570922 shows that this T form of CYP11B1 is transcribed at a significantly 
lower rate than its G form; lower expression is consistent with the observed inefficiency of 11β-
hydroxylation [8]. 
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Given the presence of a common functional SNP within CYP11B2 that is significantly associated 
with levels of cortisol, a steroid that influences blood pressure, there is strong evidence to suggest 
that CYP11B1, like CYP11B2, is a blood pressure locus. As with CYP11B2, support comes from rare 
monogenic disorders of CYP11B1. Various inactivating mutations at this locus have been described 
that result in deficient 11β-hydroxylation and, depending on their severity, reduced or completely 
absent cortisol production. The consequent accumulation of ACTH-dependent 11-
deoxycorticosterone (DOC), which has mineralocorticoid properties, can in such instances be high 
enough to result in severe hypertension. Efforts to attain normal levels of cortisol lead to elevated 
ACTH secretion and hyperplasia of the adrenal cortex [21]. 
The observation that these two key genes of the corticosteroid pathway are each capable 
independently of influencing blood pressure would be interesting enough in itself, but their physical 
linkage adds an extra dimension that is likely to augment their hypertensive role. As mentioned 
previously, our analysis of the digenic CYP11B1/CYP11B2 locus on chromosome 8 shows that LD 
extends across both genes, such that the presence of a particular allele at a polymorphic site in 
CYP11B1 is a strong indicator that a particular polymorphic form exists within CYP11B2. This is the 
case for the two functional SNPs we have described: the C form of rs13268025 at CYP11B2, which is 
associated with a raised aldosterone excretion rate, is in significant LD with the T form of rs142570922 
at CYP11B1, which is associated with reduced 11β-hydroxylation. These two potentially hypertensive 
alleles tend, therefore, to be co-inherited. Furthermore, we propose that their combined effect on 
blood pressure may be synergistic. 
Our proposed mechanism for this arises from three separate elements. The first two have already 
been mentioned with reference to severe monogenic 11β-hydroxylase deficiency: the massive rise in 
ACTH secretion and the expansion of adrenocortical volume it causes in an attempt to restore cortisol 
biosynthetic capacity. The third element concerns a known but, we would argue, underappreciated 
factor in aldosterone biosynthesis: its regulation by ACTH. ACTH acutely stimulates aldosterone 
biosynthesis by both increasing adrenal blood flow and interacting with specific G protein-coupled 
receptors in the zona glomerulosa, which influences the expression of steroidogenic genes containing 
cAMP-responsive elements; these include CYP11B2 [22]. However, several studies showed that 
prolonged administration of ACTH could not sustain aldosterone secretion and that it would fall 
back to basal levels after approximately three to five days [23–25]. Although the mechanism for this 
suppression remains unknown, such findings feed the general perception that ACTH cannot 
influence aldosterone biosynthesis for anything other than short periods of time, and that its long-
term effect is inhibitory. However, we have proposed that the suppression of aldosterone 
biosynthesis under chronic exposure to ACTH is a consequence of abnormally high doses, whereas 
chronic exposure to only mildly increased endogenous ACTH secretion could permit the sustainable 
stimulation of aldosterone secretion [3]. We examine evidence for this in greater detail below but, for 
now, let us consider the consequences for individuals carrying the T form of rs142570922 at CYP11B1 
if such a prolonged and increased ACTH influence on aldosterone were to exist. As the indisputably 
prime regulator of cortisol biosynthesis and of CYP11B1 expression, carriers of this polymorphism 
would experience mild, relative 11β-hydroxylase inefficiency due to the slight reduction in 
transcriptional efficiency it causes. Such individuals would have to prevent the small but significant 
drop in cortisol biosynthesis that would result by increasing ACTH secretion slightly but chronically. 
Although analogous to the increased ACTH release observed in severe 11β-hydroxylase deficiency, 
we argue that this milder form would differ in two key ways. Firstly, hypertrophy of the adrenal 
cortex would be a much slower and more gradual process, reflecting the relatively small rise in ACTH 
level. Secondly, the magnitude of this increase would not be sufficient to trigger the suppression of 
aldosterone secretion commonly observed when the adrenal cortex is chronically exposed to higher 
levels of ACTH. Instead, over the lifetime of its carriers, the rs142570922 T polymorphism at CYP11B1 
would induce very gradual hypertrophy and a mild but sustained elevation of aldosterone 
biosynthesis through ACTH stimulation. As we have observed, this polymorphism cannot be 
considered in isolation: it is highly likely to be co-inherited alongside the C form of rs13268025 at 
CYP11B2, which itself also predisposes to slightly increased aldosterone secretion. Furthermore, as a 
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component of the adrenocortical hypertrophy consequent upon raised ACTH, there is likely to be 
zona glomerulosa hypertrophy, further increasing its aldosterone biosynthetic capacity and/or its 
responsiveness to stimulators of aldosterone secretion such as angiotensin II (or ACTH itself). In 
summary, due to the interplay of these two linked polymorphisms at adjacent steroidogenic genes, 
we anticipate a small but chronic rise in ACTH which, over a lifetime, significantly increases 
aldosterone secretion and drives genetically predisposed carriers toward hypertension. 
This mechanism was first proposed several years ago [26] and, although we have since been able 
to refine and confirm certain details, certain aspects remain unproven. This is largely due to the subtle 
and extremely long-term nature of the proposed effects, which are too small to measure or detect, 
and to the difficulty in demonstrating that such a small increase in ACTH secretion would stimulate 
aldosterone secretion without causing the inhibition of secretion many still associate with long-term 
exposure. There is some further supporting evidence: in a small group of patients subjected to low-
dose dexamethasone suppression, those who were homozygous for the T form of rs142570922 at 
CYP11B1 had a small but significantly higher level of plasma ACTH compared to G homozygotes. 
Plasma cortisol levels did not change significantly between the different genotypes, but there was an 
apparent trend towards a raised cortisol:ACTH ratio in the T group [27]. This supports the existence 
of an increased ACTH drive in these individuals sustaining cortisol levels, in line with our proposal. 
Further investigation is ongoing to verify this hypothesis. For example, we have recent preliminary 
data from 100 normotensive volunteers who were infused with corticotropin-releasing hormone; this 
suggests that individuals with the genotype rs142570922 T at CYP11B1 and/or rs13268025 G at 
CYP11B2 respond more vigorously in terms of ACTH and ACTH-dependent steroids (cortisol, 
corticosterone and deoxycortisol) than individuals of the alternative genotypes [28]. 
Meanwhile, data emerging from GWAS specifically designed to identify loci of importance in 
blood pressure regulation also drew attention to the corticosteroid pathway, but the locus they were 
consistently highlighting was not CYP11B2 or CYP11B1, but CYP17A1 [29,30]. 
4. CYP17A1 
Over the last decade, GWAS methodology has been applied to numerous complex traits, 
including blood pressure, with the intention of discovering associations between disease and 
common genetic polymorphisms. Its potential to identify loci previously unsuspected to influence 
certain phenotypes was presented as a key advantage over the candidate gene approach. However, 
as GWAS results emerged, there was a common perception that such studies were not delivering on 
their initial promise and that a great number of relevant loci remained undetected (false negatives). 
Counter-arguments hold that GWAS was never intended to identify all loci contributing to a 
particular trait, and that such studies have led to new and meaningful new biological knowledge, 
while also confirming the importance of key genes and pathways previously suspected of playing a 
role in disease [31]. 
Data from blood pressure GWAS conducted on European subjects by the Global BPgen and 
CHARGE consortia were published in 2009 [29,30]. These, combined with further meta-analysis [32], 
identified a total of 28 loci significantly associated with systolic and/or diastolic blood pressure. 
CYP11B1 and CYP11B2 were not among them. However, a region on the long arm of chromosome 10 
at or near the CYP17A1 gene was consistently identified, and was associated with the greatest effect 
size of all the 28 loci: ~1 mm Hg of systolic blood pressure per allele. The tag marker employed by 
Global BPgen at this locus was rs11191548, which lies within a cluster of six genes, including 
CYP17A1; the tag marker used by CHARGE was rs1004467 [30], found within intron 3 of CYP17A1 
[29]. This association is not limited to European populations [33–38]. The same locus has recently 
been associated with birthweight, which itself inversely correlates to blood pressure in later life [39]; 
there is also evidence that control of aldosterone secretion associates with birthweight and that this 
effect may derive from the hypothalamic-pituitary-adrenal (HPA) axis [40]. In light of the compelling 
GWAS data and the known role of this gene in corticosteroid biosynthesis and blood pressure, we 
investigated it further. 
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The CYP17A1 gene encodes a microsomal cytochrome P450 enzyme commonly named for its 
catalytic function: 17α-hydroxylase. In the adrenal zona fasciculata, this enables the enzyme to 
convert pregenenolone to 17α-hydroxypregnenolone and progesterone to 17α-hydroxyprogesterone, 
which is essential to the synthesis of cortisol. However, it also possesses a lyase function enabling the 
cleavage of the C17,20 bond of each of these products. In the zona reticularis, this permits the 
production of dehydroepiandrosterone and androstenedione (CYP17A1 is also expressed in the 
gonads) [6,41]. Here, we will focus on its 17α-hydroxylase activity in the zona reticularis. 
Like CYP11B1, the CYP17A1 gene is primarily regulated by ACTH; this activates signalling 
cascades involving the intracellular second messenger cAMP, which promotes gene expression 
through the binding of transcription factors including steroidogenic factor 1 (SF-1), GATA-binding 
factor 6 (GATA-6) and sterol regulatory element-binding protein 1 (SREBP-1) [42]. Loss of 17α-
hydroxylase activity due to CYP17A1 mutation can, as with 11β-hydroxylase deficiency, reduce 
cortisol synthesis and lead to a surge in ACTH secretion, plus the accumulation of DOC [6]. This 
results in hypertension, DOC-dependent sodium accumulation, the suppression of aldosterone 
secretion and hypokalaemia; grossly raised levels of corticosterone compensate for the lack of 
cortisol. Sexual development is also affected, reflecting the role of CYP17A1 in androgen production. 
We therefore hypothesised that, as with CYP11B1 and CYP11B2, functional polymorphisms exist at 
the CYP17A1 locus, which alter the corticosteroid phenotype and influence blood pressure. To 
explain the blood pressure GWAS associations, any such polymorphism at CYP17A1 would also have 
to be in LD with the tag SNPs employed by those studies and have a fairly common frequency within 
the general population. 
Our initial screen of the entire CYP17A1 locus in a cohort of 60 normotensive volunteers 
identified 36 polymorphisms, of which 24 were common, with a MAF > 0.05 [43]. Of these 24, none 
were missense and several were intronic, although not at splice sites. We therefore focused our 
attention on the 7 SNPs that lay between the transcription start site and the limit of our sequencing, 
~2 kilobases upstream, reasoning that these might influence transcriptional regulation. Linkage 
analysis identified two distinct LD blocks: while one block contains six of the SNPs, but none of the 
GWAS tag SNPs, the other contains the remaining CYP17A1 SNP rs138009835 and is in significant 
LD with the rs1004467 SNP, shown by the CHARGE GWAS to associate with blood pressure. 
Therefore, of all the polymorphisms identified during our screen of the CYP17A1 locus, only 
rs138009835, a G/A SNP with a MAF of 0.11, located 1.8 kilobases upstream of the transcription start 
site, emerges as a SNP plausibly underlying the blood pressure GWAS association. 
Our subsequent analysis of the SNP rs138009835 in 232 hypertensive members of the British 
Genetics of Hypertension (BRIGHT) cohort showed that individuals homozygous for the major G 
allele had significantly increased THaldo excretion rates but no association with the excretion rates 
of metabolites of cortisol, deoxycortisol or androgens [43]. Reporter gene analysis also showed this G 
allele to associate with significantly higher transcriptional activity in vitro, under basal conditions 
and following dibutyryl cAMP stimulation (which is used to imitate ACTH in the H295R 
adrenocortical cell model that lacks ACTH receptors). In summary, the G form of rs138009835 
associates with higher CYP17A1 gene expression in vitro, increased aldosterone secretion in vivo and, 
through its linkage to the A allele of the rs1004467 tag SNP, raised blood pressure. 
Superficially, this appears to present a simple mechanism whereby functional changes in the 
steroidogenic CYP17A1 gene might affect aldosterone phenotype, with a corresponding effect on 
blood pressure. However, it is not immediately clear how such changes in CYP17A1 function 
translate into altered aldosterone production, given that CYP17A1 is not expressed in the zona 
glomerulosa and therefore has no direct role in aldosterone biosynthesis. One possibility is that 
CYP17A1 and aldosterone share a common regulatory factor that connects the two and underlies our 
observed effect. Interestingly, previous clinical studies conducted by our group show highly 
significant correlation of urinary THaldo excretion with that of cortisol metabolites [44]. Data from 
that same study also show correlation of these with urinary androgen metabolite excretion, implying 
that aldosterone, cortisol and androgens are under the regulation of a common factor. We propose 
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that this common factor is ACTH, and that it is a significant regulator of these steroids throughout 
life. 
5. ACTH 
Due to the presence of ACTH/cAMP-responsive elements at each gene promoter, CYP11B1, 
CYP11B2 and CYP17A1 transcription are all regulated by ACTH [22]. While the role of ACTH in 
regulating CYP11B1 and CYP17A1 (and by extension cortisol and androgen secretion) is relatively 
straightforward, its control of CYP11B2 and aldosterone production in the zona glomerulosa is more 
complex and not fully understood [45]. Our proposal that common polymorphisms of these three 
genes have a significant influence over aldosterone levels rests, in part, on ACTH having a more 
significant and enduring role in regulating its secretion than has generally been acknowledged. 
Evidence exists to support this view. 
Although early studies suggested that chronic ACTH might ultimately inhibit aldosterone 
secretion, this is not necessarily the case. Continuous ACTH infusion does indeed cause aldosterone 
to rise then fall back to baseline levels within 72 h, but ACTH administered in a pulsatile manner that 
more closely models its actual secretion maintains aldosterone secretion at a raised level over this 
time period [46]. Furthermore, ACTH appears to be an extremely potent regulator of aldosterone, 
capable of eliciting its secretion at doses far lower than those required for cortisol or DHEA [47]. That 
being the case, could ACTH be a significant driver of aldosterone secretion? Correlation does exist 
between ACTH and aldosterone levels; each follows a circadian rhythm, peaking in the morning and 
falling throughout the day [48]. While this synchronization does suggest a causative relationship 
between the two, elements of the RAAS also display diurnal variation—albeit less consistently—and 
its contribution to this effect cannot be ruled out [49]. 
ACTH is also released following physical or psychological stress and a recent study by Markou 
et al. suggests not only that ACTH release driven by such stress can promote aldosterone secretion, 
but that certain individuals are highly sensitive to this stimulus. The investigators recruited 143 
essentially hypertensive subjects, carefully phenotyped to exclude any cases of primary 
aldosteronism. To simulate low-grade chronic stress, this cohort was then given ultra-low doses (0.03 
µg) of ACTH. This caused a rise in plasma cortisol levels indistinguishable between the hypertensives 
and a normotensive control group over the 30-min study period. However, analysis of plasma 
aldosterone levels revealed that the essential hypertensives actually consisted of two distinct 
subgroups: approximately three-quarters had a small but distinct rise in plasma aldosterone, again 
identical to that of the normotensives. The remaining quarter, though, were termed “hyper-
responders” due to their aldosterone levels being approximately four times higher than those of the 
other subjects. The aldosterone:renin ratio of hyper-responders was also significantly elevated, 
suggesting the stimulatory effect of ACTH in these individuals occurs independently of the RAAS. 
Subjects then underwent a treadmill test, as a form of acute physical stress. Again, the hyper-
responders produced inappropriately high levels of aldosterone when compared to the remainder of 
the hypertensives and the normotensive group, whose responses were indistinguishable from one 
another; in contrast, the cortisol responses did not differ significantly across hyper-responders, other 
hypertensives or normotensives. Consequently, the authors proposed that the glomerulosa cells of 
the hyper-secretors are “primed by stress-induced ACTH secretion, which makes them more 
sensitive to any increase in either ACTH or renin/angiotensin II levels” and that this could be related 
to “gene mutations increasing the zona glomerulosa responsiveness to excitatory stimuli” [50]. As 
John Funder concluded in his commentary on this study, “When validated, attention should focus 
on ACTH and on the mechanism(s) whereby it elicits an exaggerated aldosterone response in a 
substantial minority of patients otherwise classified as essential hypertensives” [51]. 
6. ACTH Interaction with Polymorphic Steroidogenic Loci as a Determinant of Aldosterone 
Secretion and Blood Pressure 
ACTH levels directly influence cortisol and androgen levels, and vice versa. Rare monogenic 
deficiencies at CYP11B1 and CYP17A1 demonstrate the impact of these loci on circulating levels of 
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ACTH through feedback mechanisms. However, as we have described, there is now compelling 
evidence that ACTH is a more significant driver of aldosterone secretion than previously thought. 
This implies the existence of a complex and dynamic situation whereby three different sets of 
components each interact with and modulate the levels of one another, namely: 
(1) circulating levels of ACTH; 
(2) gene expression of ACTH-responsive steroidogenic loci (including CYP11B1 and CYP17A1, but 
also CYP11B2); 
(3) circulating levels of corticosteroids (including cortisol and androgens, but also aldosterone). 
A change in any one of these would alter the states of the other two (and probably of other, as 
yet unidentified) components involved in the homeostasis of this highly dynamic system. 
Altered responsiveness of any of these components to one another would tend to push 
individuals towards higher or lower blood pressure, adding further complexity to this system. We 
propose that such changes in sensitivity result from common polymorphisms at CYP11B1, CYP17A1 
and CYP11B2, each of which are capable of significantly influencing these genes’ expression and 
thereby shifting the balance of circulating steroids. Therefore, an individual’s ability to secrete 
aldosterone in response to a given dose of ACTH would be significantly determined by the array of 
functional polymorphisms at key steroidogenic loci. This is analogous to the ACTH sensitivity 
observed by Markou et al. [50]. Their proposal that polymorphisms at the KCNJ5 gene might 
contribute toward ‘hyper-responsiveness’ was not borne out by their sequencing of this locus. The 
genotyping of key SNPs at CYP11B2, CYP11B1 and CYP17A1 in such individuals would be of great 
interest. 
We acknowledge that the observed effects of the three key polymorphisms we have described 
at CYP11B1, CYP11B2 and CYP17A1 are not entirely consistent with a predisposition to hypertension. 
Specifically, while we found that the form of CYP17A1 causing higher activity is apparently 
associated with raised blood pressure, this runs contrary to the evidence that 17α-hydroxylation has 
an inverse relationship with blood pressure [52]. However, we propose that interaction between 
ACTH and these three loci is highly complex, and probably incorporates further factors in order to 
ultimately determine blood pressure. Therefore, we must be cautious in extrapolating the 
consequences of an isolated effect observed in vitro to the full complex system in vivo. The fact 
remains that genotype significantly affects function and will have consequences that must be 
integrated into the developing model. 
7. Conclusions 
In this article we have summarised evidence that common functional polymorphisms exist at 
the CYP11B1, CYP11B2 and CYP17A1 loci, and have hypothesised that each may predispose to 
hypertension. Previously, we had proposed ACTH via the CYP11B1 and CYP11B2 polymorphisms 
to be a key mediator in this hypertensive drive. Since then, data identifying the ACTH-regulated 
CYP17A1 gene as a key blood pressure locus, the association of a common functional CYP17A1 
polymorphism with aldosterone phenotype and the discovery that a sizeable proportion of essential 
hypertensives secrete inappropriately high levels of aldosterone in response to ACTH has led us to 
develop and refine this initial model. Our future work will focus on establishing whether these 
polymorphisms contribute towards the hyper-secretion of aldosterone in response to ACTH. 
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